Rachel Kiddell‐Monroe
Biographic Data
| ID | 8990087 |
|---|---|
| NAME | Rachel Kiddell‐Monroe |
| GIVEN NAMES | Rachel |
| FAMILY NAME | Kiddell‐Monroe |
| SIGNATURE | MONROE R K |
| AFFILIATIONS | McGill University |
| VERIFIED | No |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2014 |
| LATEST PUBLICATION YEAR | 2016 |
| H-INDEX | 0 |
ReRouting biomedical innovation
In recent years, the world has witnessed the tragic outcomes of multiple global health crises. From Ebola to high prices to antibiotic resistance, these events highlight the fundamental constraints of the current biomedical research and development (R&D) system in responding to patient needs globally.To mitigate this lack of responsiveness, over 100 self-identified "alternative" R&D initiatives, have emerged in the past 15 years. To begin to make…
Access to Medicines and Distributive Justice
The global health crisis in non‐communicable diseases ( NCDs ) reveals a deep global health inequity that lies at the heart of global justice concerns. Mirroring the HIV / AIDS epidemic, NCDs bring into stark relief once more the human consequences of trade policies that reinforce global inequities in treatment access. Recognising distributive justice issues in access to medicines for their populations, W orld T rade O rganisation ( WTO ) members…
No prominent works on this page.
Access to Medicines and Distributive Justice
The global health crisis in non‐communicable diseases ( NCDs ) reveals a deep global health inequity that lies at the heart of global justice concerns. Mirroring the HIV / AIDS epidemic, NCDs bring into stark relief once more the human consequences of trade policies that reinforce global inequities in treatment access. Recognising distributive justice issues in access to medicines for their populations, W orld T rade O rganisation ( WTO ) members…
ReRouting biomedical innovation
In recent years, the world has witnessed the tragic outcomes of multiple global health crises. From Ebola to high prices to antibiotic resistance, these events highlight the fundamental constraints of the current biomedical research and development (R&D) system in responding to patient needs globally.To mitigate this lack of responsiveness, over 100 self-identified "alternative" R&D initiatives, have emerged in the past 15 years. To begin to make…
Health Systems, Economic Evaluations, Quality of Life (2 works) · Law (2 works) · Pharmaceutical Economics and Policy (2 works) · Political science (2 works) · Access to medicines (1 work) · Biotechnology and Related Fields (1 work) · Computer Science (1 work) · Distributive justice (1 work) · Economic Justice (1 work) · Economics (1 work)